A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Trial Profile

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors IRX Therapeutics
  • Most Recent Events

    • 02 Aug 2017 According to an IRX Therapeutics media release, data from this trial will be presented at at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
    • 07 Feb 2012 Actual end date Dec 2010 added as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top